Assay measures phosphorylated tau 217, an indicator of amyloid pathology
— Assay measures phosphorylated tau 217, an indicator of amyloid pathology
by Judy George, Deputy Managing Editor, MedPage Today
August 25, 2026
• 2 min read
The FDA cleared the Elecsys pTau217 blood test to identify amyloid-beta pathology associated with Alzheimer's disease in people ages 55 and older with symptoms of cognitive decline, Roche announced Monday.
FDA clears Roche and Eli Lilly Alzheimer's blood test
Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care
FDA Clears New Alzheimer’s Blood Test
FDA clears PrecivityAD2, Alzheimer's disease blood test for as early as age 40 years
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test
FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer's, Building on Groundwork Laid by Early ADDF Investment
FDA Clears C2N Diagnostics’ PrecivityAD2® — First Alzheimer’s Blood Test for Adults with Cognitive Symptoms as Young as 40
Estados Unidos aprobó un nuevo análisis de sangre para detectar cambios asociados al Alzheimer
